Pierre Perrin-Monlouis Dernière mise à jour: 20 octobre 2021
From One Genome-Wide CGH Microarray to Precision Arrays for Diverse Clinical Research Applications
SANTA CLARA, Calif., Sept. 11, 2014
Agilent Technologies Inc. (NYSE: A) today announced the 10-year anniversary of its SurePrint Comparative Genomic Hybridization (CGH) Microarray, a market leader for cytogenetics research applications.
Microarray CGH is a molecular technique that enables exon-level detection of gains and losses in DNA copy number across the genome, providing resolution an order of magnitude or greater than traditional karyotype and BAC microarray analysis.
In 2004, Agilent started with a single, one-size-fits-all array with 44,000 probes. Today the company offers catalog and custom CGH arrays in many formats for many applications, including postnatal, reproductive and cancer research. Agilent offers the industry’s largest selection of custom array formats, ranging from 60,000 probes and eight samples to up to 1 million probes per array.
In 2006, Agilent released the world’s largest library of in silico optimized oligonucleotides with a Web application that enabled customers to create custom array designs in minutes. Agilent made these tools widely available at no charge or minimum order.
“By removing barriers to customization, researchers could quickly and easily create CGH arrays for virtually any cytogenetic research application of interest, including specialized arrays for reproductive, postnatal and cancer research,” said Jacob Thaysen, vice president and general manager of Agilent’s Diagnostics and Genomics group.
Agilent’s lasting commitment to collaboration and innovation has advanced the field of cytogenetics. In 2006, Agilent microarrays were selected for the NCI’s Cancer Genome Atlas research project, a three-year, $35 million project to identify novel genes important in cancer initiation and progression. In 2008, Agilent’s microarrays were selected for a Wellcome Trust Case Control Consortium research study of 19,000 individuals-the world’s largest human genomic copy number variation (CNV) study. In addition, Agilent CGH arrays were run on the majority of samples represented in the International Collaboration for Clinical Genomics database and cited in more than 10,000 publications.
Baylor College of Medicine, one of the first customers to begin using Agilent’s custom design capability, illustrates how innovative designs for constitutional and cancer applications have resulted in breakthroughs in cytogenetic research.
“As a long-term partner of Agilent, we congratulate the company on its significant milestone of 10 years of CGH microarray innovation,” said Art Beaudet, M.D., professor in the Department of Molecular and Human Genetics at Baylor College of Medicine.
“Agilent and Baylor College of Medicine have a decade-long history of successful array CGH collaboration on CGH innovation,” added Beaudet. “Our most recent array designs provide individual exon coverage for 1,700 genes to enable maximal detection of CNVs associated with disease. We have always been attracted to the signal-to noise-quality of the Agilent arrays. We have used thousands of array CGH assays over the past decade.”
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company’s 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Information about Agilent is available at www.agilent.com.
On Sept. 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. The new company is named Keysight Technologies, Inc. The separation is expected to be completed in early November 2014.
Forward-Looking Statements
This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding the separation of Agilent’s electronic measurement business; future revenues, earnings and profitability; the future demand for the company’s products and services; and customer expectations. These forward-looking statements involve risks and uncertainties that could cause Agilent’s results to differ materially from management’s current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of our customers’ businesses; unforeseen changes in the demand for current and new products, technologies, and services; customer purchasing decisions and timing, and the risk that we are not able to realize the savings expected from integration and restructuring activities.
In addition, other risks that Agilent faces include those detailed in Agilent’s filings with the Securities and Exchange Commission, including our latest Form 10-K and Form 10-Q. Forward-looking statements are based on the beliefs and assumptions of Agilent’s management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.
# # #
